Related Experiment Video
Updated: Feb 6, 2026

Author Spotlight: Elucidating the Pathways of TFH Cell Differentiation in Acute LCMV Challenges
Published on: April 26, 2024
STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non-Small Cell
Roshni Bibi1, Melvin George2, Koustav Sarkar1
1Cancer Immunology and Gene Technology Lab, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India.
Abstract:
Non-small cell lung cancer (NSCLC) is an aggressive malignancy necessitating innovative therapeutic approaches to augment antitumour immunity. Our study examined the function of the STAT2 protein in CD4+ T helper cells, which are essential for the immune response to cancer. We utilised CRISPR/Cas9 to ablate STAT2 in CD4+ T cells from stage I NSCLC patients (n = 30), assessing its impact on cellular function and diverse epigenetic pathways. Our findings indicate that the depletion of STAT2 markedly enhances the anti-cancer efficacy of T lymphocytes. Deletion of STAT2 diminished oxidative stress, enhanced the synthesis of advantageous TH1 cytokines. STAT2 depletion reduced DNA methylation and R-loop formation. T cells deficient in STAT2 showed enhanced efficacy in activating cytotoxic T lymphocytes to eliminate cancer cells. These findings identify STAT2 as a crucial regulator of immune function in the lung cancer microenvironment. Targeted STAT2 inhibition in tumour-reactive T cells may reinstate anti-tumour immunity, although systemic inhibition requires further research on targeted intervention strategies.
Insights
STAT2 protein depletion in CD4+ T cells enhances anti-cancer immunity in non-small cell lung cancer (NSCLC). This approach reduces oxidative stress and boosts anti-tumour responses, offering a potential therapeutic strategy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) requires novel therapies to improve anti-tumour immunity.
- CD4+ T helper cells are critical for mounting an effective anti-cancer immune response.
Purpose of the Study:
- To investigate the role of STAT2 protein in CD4+ T cells within the context of NSCLC.
- To assess the impact of STAT2 ablation on T cell function and epigenetic modifications in NSCLC patients.
Main Methods:
- CRISPR/Cas9 gene editing was used to deplete STAT2 in CD4+ T cells from stage I NSCLC patients (n=30).
- Evaluated cellular functions, epigenetic pathways, cytokine production, and T cell activation.
Main Results:
- STAT2 depletion significantly enhanced the anti-cancer efficacy of T lymphocytes.
- Reduced oxidative stress and DNA methylation, while increasing beneficial TH1 cytokine synthesis.
- STAT2-deficient T cells demonstrated improved activation of cytotoxic T lymphocytes against cancer cells.
Conclusions:
- STAT2 is identified as a key regulator of immune function in the NSCLC microenvironment.
- Targeted STAT2 inhibition in tumour-reactive T cells could restore anti-tumour immunity.
- Further research is needed for systemic STAT2 inhibition strategies.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
pH Regulation in Cells
Cytosolic pH
Under physiological conditions, the cytosolic pH is slightly more acidic than the extracellular pH. However, cells must prevent further acidification of their cytosol to...
iPS Cell Differentiation
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Regulation of Hematopoietic Stem Cells

